Page last updated: 2024-10-30

metformin and Bronchospasm

metformin has been researched along with Bronchospasm in 1 studies

Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.

Research Excerpts

ExcerptRelevanceReference
"Metformin is an antidiabetic drug; used to treat type II diabetes mellitus, metformin associated lactic acidosis has an incidence of 2-9 cases / 100,000 patients / year with high mortality (30%)."7.88[A case of severe metformin-associated lactic acidosis treated with CVVHDF and regional anticoagulation with sodium citrate]. ( Apicella, A; Beretta, E; Della Morte, M; Ferrario, M, 2018)
"Metformin is an antidiabetic drug; used to treat type II diabetes mellitus, metformin associated lactic acidosis has an incidence of 2-9 cases / 100,000 patients / year with high mortality (30%)."3.88[A case of severe metformin-associated lactic acidosis treated with CVVHDF and regional anticoagulation with sodium citrate]. ( Apicella, A; Beretta, E; Della Morte, M; Ferrario, M, 2018)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ferrario, M1
Apicella, A1
Della Morte, M1
Beretta, E1

Other Studies

1 other study available for metformin and Bronchospasm

ArticleYear
[A case of severe metformin-associated lactic acidosis treated with CVVHDF and regional anticoagulation with sodium citrate].
    Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia, 2018, Volume: 35, Issue:5

    Topics: Acidosis, Lactic; Aged; Anticoagulants; Bronchial Spasm; Combined Modality Therapy; Female; Furosemi

2018